Targeting Pharmacological and Nanotechnology Based Therapeutics for Management of Hirsutism: A Comprehensive State-of-the-Art

Hirsutism is characterized by the excessive growth of coarse hair in women, resembling the typical pattern seen in men. It affects between 5 to 10 % of females of reproductive age. Excessive hair growth often leads to significant mental and emotional anguish. Hirsutism is the result of an overabundance of androgens being secreted by the ovaries or adrenal glands. This article offers a comprehensive review of numerous causes that might provoke hirsutism which includes polycystic ovarian syndrome, Cushing syndrome, idiopathic hirsutism, insulin resistance, congenital adrenal hyperplasia, ovarian or adrenal tumors, menopause, and the use of certain drugs. Polycystic ovary syndrome and ovarian tumors are frequent underlying factors of hyperandrogenism, which subsequently results in the development of Hirsutism. Mechanical and cosmetic hair removal methods are viable options for managing hirsutism. This study examines the pharmacological therapies that have proven essential in enhancing the quality of life for patients. These treatments include oral contraceptives, antiandrogen therapy like spironolactone, cyproterone acetate, flutamide, and finasteride, specific insulinlowering medicines, gonadotrophin-releasing hormone agonists, and topical treatment such eflornithine hydrochloride cream (13.9% w/w cream). This review also explored significance of nanotechnology-based methods like nanostructured lipid carriers, solid lipid nanoparticles, liposomes, cerosomes, and nanogel in enhancing the effectiveness of medications used to treat hirsutism. A comprehensive update has been made to the latest information on clinical studies and patents linked to the treatment of hirsutism.